InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $17.750 0.91 (5.40%)+
Announcement
Release
20 Aug 2026 8:42AM
Price at Release
$16.840
Full Release
download
Summary
Telix Pharmaceuticals Limited's HY26 results presentation highlights strong financial performance with a 22% year-on-year revenue growth, reaching $477 million. The company reported a 148% increase in EBITDA and a net profit of $38 million, up by $41 million from the previous year. Key growth drivers include the global expansion of their Precision Medicine portfolio and strategic alliances, such as the collaboration with Regeneron. The presentation also details Telix's significant investments in R&D to support their expanding pipeline, including the development of new therapeutic candidates like TLX597-Tx and initiatives to double the total addressable market with new diagnostic indications. The company is strategically focused on expanding manufacturing capabilities and maintaining robust commercial execution to support future therapeutic launches.
Key Points
  • Revenue up by 22% year-on-year to $477 million.
  • EBITDA increased by 148% to $52 million.
  • Net profit reached $38 million, an increase of $41 million from the previous year.
  • Strong growth in the Precision Medicine portfolio.
  • Collaboration with Regeneron to develop next-generation therapies.
  • Significant R&D investments for pipeline expansion.
  • Introduction of TLX597-Tx and new diagnostic indications.
  • Expansion of manufacturing capabilities and global market reach.
  • Focus on commercial execution to support therapeutic launches.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.